UK markets close in 3 hours 48 minutes
  • FTSE 100

    6,638.39
    +49.86 (+0.76%)
     
  • FTSE 250

    21,254.68
    +33.22 (+0.16%)
     
  • AIM

    1,190.45
    -1.72 (-0.14%)
     
  • GBP/EUR

    1.1578
    +0.0025 (+0.21%)
     
  • GBP/USD

    1.3921
    +0.0001 (+0.01%)
     
  • BTC-GBP

    35,021.21
    +602.33 (+1.75%)
     
  • CMC Crypto 200

    981.16
    -5.49 (-0.56%)
     
  • S&P 500

    3,901.82
    +90.67 (+2.38%)
     
  • DOW

    31,535.51
    +603.14 (+1.95%)
     
  • CRUDE OIL

    60.73
    +0.09 (+0.15%)
     
  • GOLD FUTURES

    1,728.20
    +5.20 (+0.30%)
     
  • NIKKEI 225

    29,408.17
    -255.33 (-0.86%)
     
  • HANG SENG

    29,095.86
    -356.71 (-1.21%)
     
  • DAX

    14,089.89
    +77.07 (+0.55%)
     
  • CAC 40

    5,830.98
    +38.19 (+0.66%)
     

Outlook on the Biobanking Global Market to 2027 - Opportunity Analysis and Industry Forecasts

Research and Markets
·8-min read

Dublin, Feb. 12, 2021 (GLOBE NEWSWIRE) -- The "Biobanking Market by Specimen Type, Type of Biobank, Ownership, and Application: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global biobanking market was valued at $37. 93 billion in 2019, and is estimated to reach $57. 67 billion by 2027, growing at a CAGR of 4. 6% from 2020 to 2027.

Biobank is a biorepository meant to collect and preserve biological materials that are used for diagnosis, biodiversity studies, and research. In addition, it is used to support the research of most common types of genetic disorders to develop personalized medicines and to maintain and update database of diseases related to age.

The rise in funding by private & government organizations for biobanking and increase in application areas of bio banked samples are the major factors that drive the growth of the global biobanking market. Moreover, upsurge in incidence of diseases such as cancer significantly contributes toward the market growth, owing to the fact that biobanked specimens are used in the treatment of several chronic diseases. However, ethical issues related to biobanking and lack of awareness about it are expected to impede the market growth. On the contrary, advancements in stem cell research and unmet medical needs in emerging nations are anticipated to provide lucrative opportunity for the market expansion.

The rise in genomic research activities acts as a key driving force of the global market. Furthermore, government is taking multiple initiatives to support regenerative medicine research, which is expected to boost the market growth. Moreover, increase in demand for cost-effective drug delivery & development accelerates the market growth. Furthermore, usage of human biospecimens is increasing in cohort studies. Number of registered clinical studies with the National Institutes of Health (NIH) increased from 181,305 in 2014 to 262,445 in 2017. A substantial number of large ongoing cohort studies related to precision medicine have fomented the establishment of population-based banks.

The global biobanking market is segmented into specimen type, type of biobank, ownership, application, and region. Depending on specimen type, the market is categorized into blood products, solid tissue, cell lines, nucleic acid, and others. On the basis of ownership, it is divided into national/regional agencies, nonprofit organization, universities, and private organization. The applications covered in the study include therapeutic and research. By type of biobank, the market is bifurcated into population-based biobank and disease-oriented biobank. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global market for biobanks are BioIVT & Elevating Science, Geneticist Inc, Firalis S. A., AMS biotechnology Ltd. (AMSBIO LLC), and US Biolab Corporation, Inc., ProteoGenex, Inc., Cureline, Inc., Bay Biosciences LLC, CTI Biotech, and Boca Biolistics.

Key Benefits

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global biobanking market to identify the prevailing opportunities.

  • This study presents the competitive landscape of the global market to predict the competitive environment across geographies.

  • Comprehensive analysis of factors that drive and restrict the market growth is provided.

  • Region- & country-wise analysis is provided to understand the market trends and dynamics.

Key Topics Covered:

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.1. Research Methodology
1.1.1. Secondary Research
1.1.2. Primary Research
1.1.3. Analyst Tools and Models

Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.2. Cxo Perspective

Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Player Positioning
3.3. Porter'S Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers, Restraints, and Opportunity
3.4.2. Drivers
3.4.2.1. The Rise in Funds for Biobanks
3.4.2.2. Increase in R&D Activities for Application of Biobank Specimens
3.4.2.3. Surge in Prevalence of Fatal Chronic Diseases
3.4.3. Restraints
3.4.3.1. Legal and Ethical Issues of Biobanking
3.4.3.2. Lack of Awareness Toward Biobanking
3.4.4. Opportunity
3.4.4.1. High Growth Potential in Developing Countries
3.5. Impact of Covid-19 on Biobanking Market
3.5.1. Overview
3.5.2. Impact Analysis
3.5.3. List of 10 Largest Biobanks Across the Globe

Chapter 4: Biobanking Market, by Specimen Type
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Blood Products
4.2.1. Key Market Trends and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Analysis, by Country
4.3. Solid Tissues
4.3.1. Key Market Trends and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Analysis, by Country
4.4. Cell Lines
4.4.1. Key Market Trends and Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Analysis, by Country
4.5. Nucleic Acid
4.5.1. Key Market Trends and Opportunities
4.5.2. Market Size and Forecast, by Region
4.5.3. Market Analysis, by Country
4.6. Others
4.6.1. Key Market Trends and Opportunities
4.6.2. Market Size and Forecast, by Region
4.6.3. Market Analysis, by Country

Chapter 5: Biobanking Market, by Type of Biobank
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Population-Based Biobanks
5.2.1. Key Market Trends and Opportunities
5.2.2. Market Size and Forecast, by Region
5.2.3. Market Analysis, by Country
5.3. Disease-Oriented Biobanks
5.3.1. Key Market Trends and Opportunities
5.3.2. Market Size and Forecast, by Region
5.3.3. Market Analysis, by Country

Chapter 6: Biobanking Market, by Ownership
6.1. Overview
6.1.1. Market Size and Forecast
6.2. National/Regional Agencies
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, by Region
6.2.3. Market Analysis, by Country
6.3. Nonprofit Organization
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, by Region
6.3.3. Market Analysis, by Country
6.4. Universities
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, by Region
6.4.3. Market Analysis, by Country
6.5. Private Organization
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, by Region
6.5.3. Market Analysis, by Country

Chapter 7: Biobanking Market, by Application
7.1. Overview
7.1.1. Market Size and Forecast
7.2. Therapeutic
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, by Region
7.2.3. Market Analysis, by Country
7.3. Research
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, by Region
7.3.3. Market Analysis, by Country

Chapter 8: Biobanking Market, by Region
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia-Pacific
8.5. LAMEA

Chapter 9: Company Profiles
9.1. Ams Biotechnology Ltd. (Amsbio LLC)
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Operating Business Segments
9.1.4. Product Portfolio
9.2. Bay Biosciences LLC
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Operating Business Segments
9.2.4. Product Portfolio
9.3. Bioivt & Elevating Science
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Operating Business Segments
9.3.4. Product Portfolio
9.3.5. Key Strategic Moves and Developments
9.4. Boca Biolistics
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Operating Business Segments
9.4.4. Product Portfolio
9.5. Cti Biotech
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Product Portfolio
9.6. Cureline, Inc.
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Operating Business Segments
9.6.4. Product Portfolio
9.7. Firalis S. A.
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Operating Business Segments
9.7.4. Product Portfolio
9.8. Geneticist Inc.
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Operating Business Segments
9.8.4. Product Portfolio
9.9. Proteogenex, Inc.
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Operating Business Segments
9.9.4. Product Portfolio
9.10. Us Biolab Corporation, Inc.
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Operating Business Segments
9.10.4. Product Portfolio

For more information about this report visit https://www.researchandmarkets.com/r/5gm10t

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900